Celery allergens in patients with positive double-blind placebo-controlled food challenge.
BACKGROUND
Recently, for the first time, allergy to celery was confirmed by double-blind placebo-controlled food challenge (DBPCFC). Api g 1, Api g 4, cross-reactive carbohydrate determinants (CCD), and a 60 kDa allergen have been described as celery allergens.


OBJECTIVE
To get insights in IgE responses of patients with a positive DBPCFC to celery tuber (celeriac) compared with patients with a negative challenge test.


METHODS
Specific IgE to native and heated celery tuber and to recombinant Api g 1, the major celery allergen, were determined by enzyme allergosorbent test and immunoblotting. IgE binding to Api g 1, Api g 4, and CCD was confirmed by inhibition experiments that used recombinant Api g 1, recombinant Api g 4, pure N-glycans, and extracts of celeriac, lychee fruit, and pollens of birch, mugwort, and timothy grass as inhibitors.


RESULTS
Immunoblotting with sera from 22 patients with a positive DBPCFC to celeriac confirmed the presence of known allergenic structures: The major allergen Api g 1 (16 kDa) was recognized by IgE from 13 of 22 patients (59%). Another major allergen was CCD, determined by IgE reactivity in 12 of 22 patients (55%). Celery profilin, Api g 4, was recognized by IgE from 5 of 22 patients (23%).


CONCLUSIONS
Our DBPCFC-positive patients exclusively presented IgE to known celery allergens, although the prevalences were slightly different than were previously reported. No obvious differences were found in patients with positive IgE antibody but negative challenge test. IgE binding to all 3 structures in celeriac extract was inhibited by birch pollen extract, whereas mugwort pollen extract could only inhibit IgE reactivity to Api g 4 and CCD. Inhibition experiments with a purified carbohydrate moiety clearly showed that the IgE epitope mannose-xylose-fucose-glycan (Manalpha1-6[Xylbeta1-2]Manbeta1-4GlcNAcbeta1-4[ Fucalpha1-3]GlcNAc) or a closely related structure is present in celeriac extract and is important in patients with clinical allergy to celery.
Lüttkopf
D
D
Department of Allergology, Paul-Ehrlich-Institut, Langen, Germany.
Ballmer-Weber
B K
BK
Wüthrich
B
B
Vieths
S
S
D000284:Administration, Oral; D000485:Allergens; D052179:Antigens, Plant; D019661:Apiaceae / Q000009:adverse effects / Q000276:immunology*; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005512:Food Hypersensitivity / Q000209:etiology*; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting; D010919:Placebos; D010940:Plant Proteins / Q000276:immunology; D011485:Protein Binding / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology
D000485:Allergens; D052179:Antigens, Plant; C096695:Api g 1 protein, Apium graveolens; D006020:Glycopeptides; D010919:Placebos; D010940:Plant Proteins; D011994:Recombinant Proteins